Latest in News & Research
What It Means to Treat Something That Doesn’t Behave Consistently
Atopic dermatitis rarely behaves the same way twice, which means the real work of treating it begins in everything we don’t immediately see.
Nailing Down a Diagnosis: When Dermatology Is Not Just Skin Deep
Sometimes the smallest structure in the exam, the nail, offers some of the clearest clues to what’s really going on beneath the surface.
International Severity Criteria Developed for Vitiligo
Major criteria for vitiligo include spread or active disease, involvement of highly visible or high-impact areas, psychological distress
AAD: Zasocitinib Safe, Effective for Moderate-to-Severe Plaque Psoriasis in Adults
Phase 3 studies show the highly selective oral tyrosine kinase 2 inhibitor provides rapid, durable skin improvement
AAD: Upadacitinib Safe, Effective for Nonsegmental Vitiligo
Benefits include total and facial repigmentation in patients 12 years and older versus placebo
AAD: Ixekizumab + Tirzepatide Boosts Psoriatic Arthritis Outcomes More Than Ixekizumab Monotherapy
Ixekizumab plus tirzepatide tied to simultaneous benefit of American College of Rheumatology 50 percent improvement and weight reduction
AAD: Subcutaneous Amlitelimab Aids Atopic Dermatitis Outcomes Through Week 24
Findings seen for skin clearance and disease severity with both every-four-week and every-12-week dosing
Topical Melatonin Demonstrates Anti-Aging Effects in Human Skin
Topical melatonin improves hydration and firmness and reduces wrinkle depth and surface roughness in clinical studies
AAD: AI-Based Medical Device Has High Accuracy for Skin Cancer
Sensitivity of DERM+ for identifying melanoma was 93.7 percent and for SCC, BCC was 100 and 99.2 percent
No Link Found Between Childhood Atopic Dermatitis and Markers of Cardiovascular Risk
Authors say universal screening of all children with atopic dermatitis is unlikely to improve identification of early cardiovascular risk
Patients With Psoriasis Have Elevated Risk for Complications After Total Hip Arthroplasty
Higher superficial SSI, deep SSI, wound complications, sepsis, aseptic revision reported for those with cutaneous psoriasis
AAD: Significant Benefits Seen for Brepocitinib 30 mg in Dermatomyositis
Mean Total Improvement Score significantly improved at week 52; brepocitinib was superior for all nine secondary outcomes
AAD: Timolol Maleate Gel Effective for Superficial Infantile Hemangioma
Topical timolol maleate 0.5 percent gel applied three times daily for 24 weeks is effective and safe
Risk for Skin Cancer Elevated for Patients With Chronic Lymphocytic Leukemia
Patients with CLL have increased risk for most skin cancer subtypes and higher risk for skin cancer-specific metastasis and death
FDA Drops Plan To Ban Tanning Beds for Minors Nationwide
Experts warn tanning beds raise skin cancer risk
FDA Approves Icotyde for Moderate-to-Severe Plaque Psoriasis
Icotyde is the first and only targeted oral peptide that blocks the IL-23 receptor
Punch Excision Plus Radiotherapy Effective for Trunk Keloids
Perioperative and postoperative RT yield equivalent cosmetic outcomes at 18 months postoperatively
AI Achieves Comparable Melanoma Diagnostics to Dermatologists
Higher sensitivity and specificity seen in single study reporting on AI-assisted dermatologists
Risk for Death Reduced With Sentinel Node Biopsy in Melanoma
Significantly reduced risk for death from melanoma and reduced risk for recurrence reported for those undergoing SNB
Early-Onset Androgenetic Alopecia Linked to Diabetes Mellitus Risk
Androgenetic alopecia linked to DM, impaired fasting glucose in adults younger 45 years but not those older than 45 years
Dupilumab Restores Skin Barrier Function in Pediatric Atopic Dermatitis
No significant differences seen in transepidermal water loss, epidermal thickness for AD versus healthy skin at weeks 16 and 28
Roflumilast Cream Has Long-Term Safety, Efficacy in Young Children
Atopic dermatitis signs/symptoms continued to improve at treatment week 56 among children aged 2 to 5 years
AAAAI: No Increase Seen in Asthma Exacerbations With ICI Use for Melanoma, Renal Cell Carcinoma
Patients receiving pembrolizumab or nivolumab exhibited modest reduction in exacerbation rates at 24 months
24 of 1238